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Abstract: DJ-1 deglycase is a protein with anti-oxidative and anti-apoptotic properties and its role in
oncogenesis is controversial. Indeed in primary breast cancer and non-small-cell lung carcinoma, its
higher expression was shown in more aggressive tumors while in other neoplasms (e.g., pancreatic
adenocarcinoma), higher expression was related to better prognosis. Beclin has a relevant role in
autophagy and cellular death regulation, processes that are well known to be impaired in neoplastic
cells. DJ-1 shows the ability to modulate signal transduction. It can modulate autophagy through
many signaling pathways, a process that can mediate either cell survival or cell death depending
on the circumstances. Previously, it has been suggested that the involvement of DJ-1 in autophagy
regulation may play a role in tumorigenesis. The aim of our study was to investigate the link
between DJ-1 and Beclin-1 in glioblastoma through the immunohistochemical expression of such
proteins and to correlate the data obtained with prognosis. Protein expression was assessed by
immunohistochemistry and the immunoscores were correlated with clinicopathologic parameters.
Kaplan–Meier survival curves were generated. A statistically significant association between DJ-1
score and recurrence (p = 0.0189) and between the former and Isocitrate Dehydrogenase 1 (IDH1)
mutation (p = 0.0072) was observed. Kaplan–Meier survival curve analysis revealed that a higher DJ-1
score was associated with longer overall survival (p = 0.0253, k2 = 5.005). Furthermore, an unexpected
direct correlation (p = 0.0424, r = 0.4009) between DJ-1 and Beclin score was evident. The most
significant result of the present study was the evidence of high DJ-1 expression in IDH-mutant
tumors and in cases with longer overall survival. This finding could aid, together with IDH1, in the
identification of glioblastomas with better prognosis.
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1. Introduction
Glioblastoma represents the most common form of brain tumor among adults (15% of all
intracranial neoplasms and 45% of primitive brain tumors) [1]. In 2016, the World Health Organization
drafted a new classification system for brain tumors [2] that was based on the integration of
morphological and molecular data. Glioblastoma is the most aggressive form (grade IV) of glioma and
its morphology consists of the coexistence of four variables: nuclear atypia, mitoses, microvascular
proliferation and necrosis.
Two main families of glioblastoma were identified, Isocitrate Dehydrogenase (IDH)-mutant
and IDH-wild type glioblastomas, which represent two different clinicopathological diseases,
the histopathology of which can be absolutely indistinguishable. IDH-wild type glioblastomas
are the most frequent (90%). They are usually diagnosed at a median age of 62 years, with a median
overall survival of 15 months after therapy (based on surgery plus chemotherapy and radiotherapy).
In IDH-mutant glioblastomas, the median age at diagnosis is 44 years and with a median overall
survival of 31 months after therapy. Other molecular alterations (p53, ATRX, TERT promoter mutations,
EGFR amplification and mutations, etc.) can be detected in these tumors but not one is specific of
each subtype.
DJ-1 deglycase (also called PARK7, Parkinson’s disease protein 7) is a protein with anti-oxidative
and anti-apoptotic properties [3,4]. Under oxidative conditions, DJ-1 inhibits α-sinuclein aggregation
through its chaperon activity, working as an oxidative stress sensor. Its oncogenic role was identified,
for the first time, as a repressor of Phoshphatase and tensin Homolog (PTEN), inducing proliferation
in primary breast cancer and primary non-small-cell lung carcinoma samples. It was observed [5–8]
that a higher expression of DJ-1 was more common among cases with worse prognosis. Conversely,
in cases of pancreatic and endometrial adenocarcinomas [9,10], the higher expression of the protein
was related to a good prognosis.
Beclin is a protein with an essential role in autophagy and cellular death regulation [11], hence
in tumorigenesis and in neurodegeneration. Furthermore, the caspase-mediated cleavage of Beclin
1 promotes crosstalk between apoptosis and autophagy [12]. Schizophrenia is linked to low levels
of this protein in hippocampal tissue. Autophagy is a process that is preserved in evolution and it
consists of the degradation of structural proteins and organelles. Its relationship with cancer is well
known: in neoplastic cells, this process is impaired. The monoallelic deletion of the Beclin gene is
observed in 40–75% of cases of sporadic breast cancer [13], and its heterozygous loss is associated with
a higher proliferative rate and lower autophagy. These findings are indicative of a role for Beclin as a
tumor suppressor [14,15]. It was observed that in those ovarian cancers [16] where autophagy was
hyper-regulated, the lesion was less aggressive and more chemosensitive.
DJ-1 has the ability to modulate signal transduction. It can modulate autophagy through many
signaling pathways, a process that can mediate either cell survival or cell death depending on the
circumstances [17]. Previously, it has been suggested that the involvement of DJ-1 in autophagy
regulation may play a role in tumorigenesis [18]. In particular, the overexpression of DJ-1 may inhibit
Beclin 1 transcription.
The expression of DJ-1 in glioblastomas was studied, for the first time, in a series of 40 cases [19].
The study showed a direct correlation between the protein and p53, and an inverse association with
EGFR. Furthermore, it was observed that DJ-1 was expressed more in astrocytes than in neurons,
especially in reactive astrocytes, both in acute (e.g., infarction) and chronic (e.g., Parkinson’s disease)
forms. In vitro experiments [20] suggest that its low expression makes cells more vulnerable. This
observation is in favour of a possible role for this protein in promoting survival. In glioblastomas, DJ-1
positively modulates anti-apoptotic processes through two relevant pathways: one involving p53 and
one through tyrosine kinases (EGFR, PI3K, Akt e PTEN). However, although this molecular link exists,
the over-expression of DJ-1 is not effective enough to induce neoplastic transformation, unless there is
co-transfection with another factor (e.g., Ras). Furthermore, astrocytes that chronically overexpress
DJ-1 do not develop neoplasms, neither were any genetic mutations of DJ-1 detected in glioblastoma
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cases in studies on sequencing. In a case series of 76 ependymomas [21], the higher expression of the
protein was observed in cases with a worse prognosis, as well as in higher-grade tumors in a study of
88 gliomas [22].
Most of the knowledge concerning the role of Beclin in gliomas is based on cell cultures. One
study [23] evaluated the immunohistochemical expression of the protein and showed higher levels in
tumor tissue compared to normal brain tissue, independently from tumor grade and overall survival.
The aim of our study was to investigate the link between DJ-1 and Beclin-1 in glioblastoma
through the immunohistochemical expression of such proteins and to correlate the data obtained
with prognosis.
2. Results
Of the 26 examined cases (Table 1), 17 were male and nine were female, aged between 35 and 81
years (median age of 63 years). All the patients were affected by a glioblastoma that was “localized” in
the temporal, frontal and parietal lobe in 13, four and two cases, respectively, and “extended” in the
fronto-temporal, tempo-parietal, tempo-parietal-occipital and parieto-occipital lobe in two, three, one
and one cases, respectively. Three cases (cases 24, 25 and 26) were excluded from survival studies, as
there was not enough follow-up time, since the patients are still alive and the surgery was performed
less than 6 months ago. Overall survival was between 1 and 84 months. Disease recurrence was
recorded in 16 of the 23 cases, with disease-free survival time ranging between 1 and 47 months.
Table 1. Clinico-patohologic features of the collective.
Case Sex Age Site IDH1 DJ-1 Beclin Recurrence O.S.*
1 F 62 Right temporal wt 1 0 24 84
2 F 70 Right temporal wt 1 3 no 10
3 M 35 Left temporal mut 2 2 47 48
4 F 41 Right frontal mut 2 2 24 36
5 F 58 Left posterior frontal wt 2 2 2 12
6 M 74 Left temporal wt 3 3 12 15
7 M 60 Left temporale wt 0 1 no 12
8 M 57 Right frontal-temporal wt 0 3 no 48
9 F 36 Left posterior temporal wt 1 1 12 24
10 M 69 Right temporal wt 1 0 9 13
11 F 72 Left temporal wt 3 2 36 64
12 M 73 Left posterior parietal wt 1 2 10 11
13 M 71 Left parietal wt 1 2 8 9
14 M 41 Right temporal mut 3 3 8 15
15 M 52 Left temporal mut 3 3 3 20
16 M 63 Left frontal mut 3 3 10 25
17 M 61 Left temporal-parietal wt 2 2 12 28
18 M 69 Right frontal-temporal wt 1 3 13 13
19 F 81 Right parietal-occipital wt 0 3 11 14
20 F 72 temporal-parietal-occipital wt 1 1 no 1
21 M 62 Right temporal wt 1 1 no 9
22 M 75 Right temporal wt 0 1 no 1
23 M 63 Right frontal wt 2 1 no 13
24 M 70 Right temporal-parietal mut 3 3 n.a. n.a.
25 M 72 Left temporale mut 0 1 n.a. n.a.
26 F 39 Left frontal-parietal mut 3 2 n.e. n.e.
OS*: overall survival; n.a.: not available because follow-up time was insufficient (<6 months) in patients still alive.
A total of eight cases showed cytoplasmic reactivity to the IDH1 protein, a finding that was
indicative of the presence of point mutation R132H in the IDH1 gene.
In all glioblastomas, the DJ-1 protein was expressed (Figure 1a–c) with a nuclear and cytoplasmic
variable signal in 21 cases (9, 5 and 7 cases, respectively showed signal 1, 2 and 3 score).
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Figure 1. Immunohistochemical staining was evaluated with a four-tiered scoring system for both DJ-
1 (a–c) and Beclin (d–f). DJ-1 nuclear and cytoplasmic/nuclear Beclin reactivity was observed in <10% 
of neoplastic cells in cases with a score of 1, in 10–50% of neoplastic cells in cases with a score of 2 and 
in ≥50% of neoplastic cells in cases with a score of 3. Score 0 was used in the absence of staining (200× 
magnification). 
The Beclin protein (Figure 1d–f) was negative in two cases and showed a signal with a score of 
1 in seven cases, a score of 2 in eight cases and a score of 3 in nine cases. Spearman’s test highlighted 
a direct correlation between DJ-1 and Beclin score that was statistically significant (p = 0.0424, r = 
0.4009) (Figure 2). 
 
Figure 2. Spearman’s test revealed a direct correlation between DJ-1 and Beclin immunoscore (p = 
0.0424, r = 0.4009). 
Fisher’s exact test revealed a statistically significant association (Figure 3) between DJ-1 score 
(0/1 vs. 2/3) and recurrence (p = 0.0189) and between the former and IDH1 mutation (p = 0.0072). 
Furthermore, a slight tendency (Figure 4) to a more frequent relapse occurrence was observed in cases 
with a higher Beclin score (scores 2/3), without reaching statistical significance (p = 0.0657). 
Figure 1. I unohistoche ical staining as e al ate it i i 1
(a–c) and Beclin (d–f). DJ-1 nuclear and cytoplasmic/nuclear Beclin reactivity was observed in <10% of
neoplastic cells in cases with a score of 1, in 10–50% of neoplastic cells in case with a score of 2 and in
≥50% of neoplastic cells in case with a score of 3. Score 0 was used in t f t i i (200×
magnification).
The Beclin protein (Figure 1d–f) was negative in two cases and sho ed a signal ith a score of 1
in sev n cases, a score of 2 in eight case and a score of 3 in i e cases. Spearman’s test highlighted a
direct correlation betw en DJ-1 and Beclin score that was statistically significa t (p = 0.0424, r = 0.4009)
(Figure 2).
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Fisher’s exact test revealed a statistically significant association (Figure 3) between DJ-1 score
(0/1 v . 2/3) and recurr nce (p = 0.0189) nd between the f rmer and IDH1 mutation (p = 0.0072).
Furthermore, a slight tendency (Figure 4) to a more frequent relapse occurrence was observed in cases
wit a higher Beclin score (s ores 2/3), without reaching statistical significa (p = 0.0657).
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The a l i r r es analysis showed a statistically significant difference (p = 0.0 53,
k2 = .005) in terms of overall survival in cases with a high (score of 2/3) compared to those with a low
(score of 0/1) DJ-1 reactivity: a higher s r ll s r i l (Figure 5). No
effect on overall survival was recorded for Beclin.
Furthermore, in accordance with literature data, in our small collective, it was confirmed that
cases with IDH1 gene mutation have longer overall survival than IDH wild-type forms, although
statistical significance was not reached (p = 0.0871, k2 = 2.928).
No differences in terms of progression-free survival (PFS) were recorded for IDH1, DJ-1, or Beclin.
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3. Discussion
Glioblastomas are highly aggressive high-gra e neoplasm for which, o date, not ma y therapeu ic
options are available. The new WHO Classification system ide tified two major subpopulations
that differ in terms of the presence of IDH gene mutation and overall survival. IDH- mutated forms
have longer ov rall survival and represent the minority (approximat ly 10%) in the context of a rare
neoplasm. Therefore, IDH mutation identification in glioblastoma is not of much relevance clinically.
For this reason, many research lines are underway and they are aimed toward the identification of
further prognostic factors and, eventually, predictive factors for personalized therapies.
DJ-1 is, by definition, a protein with anti-oxidant prop rties, that can preserve canc r cell survival.
Hence, an oncogenic rol shou d b the most possible. The relationship of DJ-1 protein with cancer is
controversial: in some sites, its higher expres ion is associated with w rse pr gnosis while in others,
completely opposite findings were detected.
As observed by others, DJ-1 was more and variably expressed in glioblastomas compared to
normal tissue. Furthermore, the protein showed a direct corr lation with IDH1 expression and,
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consistently, with longer overall survival to disease. In glioblastoma, its clinical application could
support IDH1 in achieving a prognostic stratification. IDH is an enzyme that catalyzes the oxidative
decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2, an irreversible
step of the citric acid cycle, due to its large negative free energy change. For this reason, it must be
carefully regulated to avoid the unnecessary depletion of isocitrate (and therefore an accumulation
of alpha-ketoglutarate). Furthermore, the mutated IDH1 protein acquires the ability to convert
α-ketoglutarate to (R)-2-hydroxyglutarate (2-HG) which could act as an oncometabolite and DJ-1 could
exert a potential protective role against oxidative stress in the tumor cells potentially triggered by 2-HG.
The correlation between DJ-1 and the IDH-1 mutated form might be related to the activity of abnormal
products of the metabolism of cancer cells since 2-HG contributes to metabolic reprogramming in
diffuse glioma and hence to oxidative stress tolerance.
In view of the high levels of the protein found in pancreatic juices in cases of pancreatic
adenocarcinoma [24], a potential role of circulating marker in the liquor or serum could be hypothesized.
It could be detected during post-surgical follow up, for an early identification of relapse by a less
invasive technique. Indeed, in our small series, DJ-1 was expressed more in cases where recurrence
was more frequent.
The results obtained for Beclin were in accordance with what is known in the literature: the
protein was expressed more in tumor tissue compared to normal tissue, but no statistically significant
association with clinicopathological features was observed.
The only significant data was the direct correlation between DJ-1 and Beclin, an apparently
unusual association that remains unclear, since the former is an anti-apoptotic protein and the
other mainly performs an autophagic function. However, it is known that Beclin contains a
Bcl2-homology-3 (BH3) domain and, in general, the “BH3-only members” of Bcl-2 family can bind to and
antagonize the pro-survival proteins, leading to increased apoptosis (12). Beclin’s anti-apoptotic role is
described in several settings including TNF-related apoptosis-inducing ligand (TRAIL), chemotherapy,
irradiation, immunotherapy, nutrient deprivation, angiogenesis inhibitors and hypoxia. Probably,
the overexpression of other factors, like High Mobility Group A (HMGA) which are general architectural
chromatin proteins, that may induce autophagy can influence both the beclin-1 and DJ-1 levels in
glioblastoma [25,26]. In an attempt to clarify the potential role of High-mobility group protein (HMGA1)
factor on the regulation of DJ-1 gene expression, we performed a search using MatInspector software
that looks for putative binding sites in DNA sequences. A total of 2000 bases upstream of the ATG
codon of human DJ-1 gene was analyzed. The analysis revealed several sequence-specific bindings
of the HMGA1 protein in a region between −2238 and −1563 bp upstream of the ATG site. Further,
in vitro experiments are needed to validate the functional action of HMGA1 on the regulation of
DJ-1 expression.
The microenvironment in which these factors operate could be decisive and could account for
their different actions in different tumor types. Glioblastomas are tumors with different biological
behaviors compared to purely epithelial tumors: the former usually show extreme local aggressiveness
and very low metastatic capacity.
4. Materials and Methods
A total of 26 cases of glioblastomas were retrieved from the archives of the Institute of Pathology
of Federico II University Hospital of Naples. They were diagnosed in the period ranging from 2004
to 2019, according to the current WHO Classification of tumours of the Central Nervous System [2].
In 23 cases, information concerning the clinical evolution (overall survival, relapse and, eventually,
time to relapse) of the disease was available. A signed informed consent to use surgical specimens for
scientific purposes was available for each patient.
All the specimens were formalin fixed and paraffin embedded. The most representative sample of
the tumor was chosen to perform immunohistochemical studies.
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After deparaffinization, slides were submerged in either sodium citrate buffer or Tris–EDTA buffer
for heat-induced epitope retrieval at 97 ◦C for 20 min. Immunohistochemistry for DJ-1 and Beclin
proteins was performed using the Polyclonal Rabbit Anti-Human DJ-1 antibody (NovusBiologicals; 1:
800 dilution) and Polyclonal Rabbit Anti-Human Beclin antibody (NovusBiologicals; 1: 1000 dilution).
Brain tissue with reactive astrocytes and adrenal medulla were chosen as a positive control, respectively
for DJ-1 and Beclin. Sections of glioblastoma stained with the secondary antibody alone were used as a
negative control.
For DJ-1 (nuclear and cytoplasmic signal) and Beclin (nuclear signal), immunoreactivity was
assessed on 10 power fields with a semiquantitative score on neoplastic cells: 0 (no staining), 1 (<10%
of cells), 2 (10−50%) and 3 (≥50%) (Figure 1). Scores 2 and 3 were considered high. Each case was
evaluated independently by three different observers and when the scores were discordant, the cases
were re-evaluated with a multi-head microscope. In all cases, IDH1 staining was automatically made
with pre-diluted antibody (dia-h09, Dianova, 1: 20 dilution).
IDH status was assessed by immunohistochemistry in most cases but in patients under the age of
54, it was also necessary to carry out molecular investigations to exclude non-canonical IDH mutations
not detectable with the antibody (IDH1 R132H). Indeed, it is well known [2] that in patients aged >54
years, the probability of having an alternative IDH mutation is <1%. Therefore, immunohistochemistry
alone may be sufficient to investigate IDH status.
For correlation studies between scores, Spearman’s test was applied, and Fisher’s exact test was
also performed for studies on the association with clinicopathological parameters (sex, age, tumor
extension, relapse and IDH status).
Kaplan–Meier survival curves for DJ-1, Beclin and IDH1 were generated with the
Gehan–Breslow–Wilcoxon test.
All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software,
La Jolla, CA, USA). A probability (p) value less than 0.05 was considered statistically significant.
5. Conclusions
Overall, the present study provides preliminary data for the evaluation of anti-apoptotic and
anti-oxidant proteins in gliomas. As already observed in other studies, DJ-1 was variably expressed
in glioblastomas. In our study, it was shown that its higher expression was related to longer overall
survival and to the IDH-mutant state. This finding could support the identification of cases with better
prognosis. It was also shown that Beclin was variably expressed in the same study but, in this case,
no correlation with clinicopathological parameters was detected. Furthermore, un unexpected direct
correlation between Beclin and DJ-1 was observed, a finding deserving further studies on cell cultures
and on a larger scale.
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